Performance of a dual-hormone closed-loop system versus insulin-only closed-loop system in adolescents with type 1 diabetes. A single-blind, randomized, controlled, crossover trial

被引:3
|
作者
Lindkvist, Emilie Bundgaard [1 ,2 ]
Laugesen, Christian [1 ,2 ]
Reenberg, Asbjorn Thode [3 ]
Ritschel, Tobias Kasper Skov [3 ]
Svensson, Jannet [1 ,4 ]
Jorgensen, John Bagterp [3 ]
Norgaard, Kirsten [1 ,2 ]
Ranjan, Ajenthen G. G. [1 ,5 ]
机构
[1] Copenhagen Univ Hosp, Steno Diabet Ctr Copenhagen, Herlev, Denmark
[2] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark
[3] Tech Univ Denmark, Dept Appl Math & Comp Sci, Lyngby, Denmark
[4] Herlev & Gentofte Univ Hosp, Dept Pediat, Herlev, Denmark
[5] Danish Diabet Acad, Odense, Denmark
来源
关键词
type 1 diabetes mellitus; adolescents; dual-hormone; advanced hybrid closed-loop; artificial pancreas; non-linear model predictive control; moderate intensity continuous exercise; ARTIFICIAL PANCREAS; OPEN-LABEL; GLYCEMIC CONTROL; PUMP THERAPY; GLUCOSE; OUTPATIENT; PAIN;
D O I
10.3389/fendo.2023.1073388
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveTo assess the efficacy and safety of a dual-hormone (DH [insulin and glucagon]) closed-loop system compared to a single-hormone (SH [insulin only]) closed-loop system in adolescents with type 1 diabetes. MethodsThis was a 26-hour, two-period, randomized, crossover, inpatient study involving 11 adolescents with type 1 diabetes (nine males [82%], mean +/- SD age 14.8 +/- 1.4 years, diabetes duration 5.7 +/- 2.3 years). Except for the treatment configuration of the DiaCon Artificial Pancreas: DH or SH, experimental visits were identical consisting of: an overnight stay (10:00 pm until 7:30 am), several meals/snacks, and a 45-minute bout of moderate intensity continuous exercise. The primary endpoint was percentage of time spent with sensor glucose values below range (TBR [<3.9 mmol/L]) during closed-loop control over the 26-h period (5:00 pm, day 1 to 7:00 pm, day 2). ResultsOverall, there were no differences between DH and SH for the following glycemic outcomes (median [IQR]): TBR 1.6 [0.0, 2.4] vs. 1.28 [0.16, 3.19]%, p=1.00; time in range (TIR [3.9-10.0 mmol/L]) 68.4 [48.7, 76.8] vs. 75.7 [69.8, 87.1]%, p=0.08; and time above range (TAR [>10.0 mmol/L]) 28.1 [18.1, 49.8] vs. 23.3 [12.3, 27.2]%, p=0.10. Mean ( +/- SD) glucose was higher during DH than SH (8.7 ( +/- 3.2) vs. 8.1 ( +/- 3.0) mmol/L, p<0.001) but coefficient of variation was similar (34.8 ( +/- 6.8) vs. 37.3 ( +/- 8.6)%, p=0.20). The average amount of rescue carbohydrates was similar between DH and SH (6.8 ( +/- 12.3) vs. 9.5 ( +/- 15.4) grams/participant/visit, p=0.78). Overnight, TIR was higher, TAR was lower during the SH visit compared to DH. During and after exercise (4:30 pm until 7 pm) the SH configuration produced higher TIR, but similar TAR and TBR compared to the DH configuration. ConclusionsDH and SH performed similarly in adolescents with type 1 diabetes during a 26-hour inpatient monitoring period involving several metabolic challenges including feeding and exercise. However, during the night and around exercise, the SH configuration outperformed DH.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] The psychosocial outcomes of advanced hybrid closed-loop system in children and adolescents with type 1 diabetes
    Jalilova, Arzu
    Pilan, Birsen Senturk
    Demir, Gunay
    Ozbaran, Burcu
    Balki, Hanife Gul
    Arslan, Emrullah
    Kose, Sezen Gokcen
    Ozen, Samim
    Darcan, Sukran
    Goksen, Damla
    EUROPEAN JOURNAL OF PEDIATRICS, 2024, 183 (07) : 3095 - 3103
  • [32] Effect of closed-loop insulin delivery system on glycemic control in an adolescent with type 1 diabetes
    Bentebbaa, F. Z.
    Rami, I.
    Rachedi, H.
    Rouf, S.
    Latrech, H.
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 : 254 - 255
  • [33] Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes
    Ware, J.
    Allen, J. M.
    Boughton, C. K.
    Wilinska, M. E.
    Hartnell, S.
    Thankamony, A.
    de Beaufort, C.
    Schierloh, U.
    Froehlich-Reiterer, E.
    Mader, J. K.
    Kapellen, T. M.
    Rami-Merhar, B.
    Tauschmann, M.
    Nagl, K.
    Hofer, S. E.
    Campbell, F. M.
    Yong, J.
    Hood, K. K.
    Lawton, J.
    Roze, S.
    Sibayan, J.
    Bocchino, L. E.
    Kollman, C.
    Hovorka, R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (03): : 209 - 219
  • [34] Low-Dose Empagliflozin as Adjunct to Hybrid Closed-Loop Insulin Therapy in Adults With Suboptimally Controlled Type 1 Diabetes: A Randomized Crossover Controlled Trial
    Pasqua, Melissa-Rosina
    Jafar, Adnan
    Kobayati, Alessandra
    Tsoukas, Michael A.
    Haidar, Ahmad
    DIABETES CARE, 2023, 46 (01) : 165 - 172
  • [35] Efficacy of Hybrid Closed-Loop System in Adults with Type 1 Diabetes and Gastroparesis
    Kaur, Harsahiba
    Schneider, Nicole
    Pyle, Laura
    Campbell, Kristen
    Akturk, Halis K.
    Shah, Viral N.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2019, 21 (12) : 736 - 739
  • [36] LOW-DOSE EMPAGLIFLOZIN AS ADJUNCT TO HYBRID CLOSED-LOOP INSULIN THERAPY IN SUBOPTIMALLY CONTROLLED ADULTS WITH TYPE 1 DIABETES: A RANDOMIZED CROSSOVER CONTROLLED TRIAL
    Pasqua, M. -R.
    Jafar, A.
    Kobayati, A.
    Tsoukas, M.
    Haidar, A.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 : A50 - A51
  • [37] Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial
    McAuley, Sybil A. A.
    Trawley, Steven
    Vogrin, Sara
    Ward, Glenn M. M.
    Fourlanos, Spiros
    Grills, Charlotte A. A.
    Lee, Melissa H. H.
    Alipoor, Andisheh Mohammad
    O'Neal, David N. N.
    O'Regan, Niamh A. A.
    Sundararajan, Vijaya
    Colman, Peter G. G.
    MacIsaac, Richard J. J.
    DIABETES CARE, 2022, 45 (02) : 381 - 390
  • [38] Open-source Closed-Loop System Is Effective for Type 1 Diabetes
    Larkin, Howard D.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (14): : 1387 - 1388
  • [39] Realizing a Closed-Loop (Artificial Pancreas) System for the Treatment of Type 1 Diabetes
    Lal, Rayhan A.
    Ekhlaspour, Laya
    Hood, Korey
    Buckingham, Bruce
    ENDOCRINE REVIEWS, 2019, 40 (06) : 1521 - 1546
  • [40] Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 × 2 factorial randomized crossover trial
    Ahmad Haidar
    Leif Erik Lovblom
    Nancy Cardinez
    Nikita Gouchie-Provencher
    Andrej Orszag
    Michael A. Tsoukas
    C. Marcelo Falappa
    Adnan Jafar
    Milad Ghanbari
    Devrim Eldelekli
    Joanna Rutkowski
    Jean-François Yale
    Bruce A. Perkins
    Nature Medicine, 2022, 28 : 1269 - 1276